In Silico Study: Comparison of Binding Affinity of Quercetin and Tak-285 Against HER2 Malignancy Protein
DOI:
https://doi.org/10.30742/jikw.v15i1.4735Keywords:
In Silico Study, Quercetin, HER2, TAK-285Abstract
Background : Cancer is a leading global health challenge, driven by various proteins that promote malignant cell growth—one of which is HER2, a transmembrane receptor tyrosine kinase in the ErbB family. TAK-285 is a known HER2 inhibitor. Recently, natural compounds like quercetin have gained attention for their ability to suppress HER2 overexpression and offer therapeutic potential. Objective: This study is to compare the binding affinity between quercetin and the reference inhibitor TAK-285 with the HER2 protein, as well as to analyze the molecular interaction patterns of HER2 using In Silico study. Through this, the study seeks the determine the potential similarity in the inhibition mechanisms of HER2 quercetin and TAK-285. Methods: Experimental study using In Silico docking methods, was performed using AutoDock Vina via PyRx 0.8 to evaluate involving docking interactions between quercetin and HER2, as well as TAK-285 and HER2. Results : The results showed that quercetin binds to HER2 with a binding energy of -8.3 kcal/mol, while TAK-285 shows a stronger affinity with -9.0 kcal/mol. Despite having a slightly lower binding affinity, quercetin successfully interacts with key residues in the HER2 binding pocket and demonstrates potential as a natural HER2 inhibitor.Conclusion: These findings suggest that quercetin may serve as a promising lead compound for HER2-targeted therapy and support further investigation through in vitro and in vivo studies.
References
Aisy, N. S. R., Juniati, L., Saputra, Y., Hidayah Putri, R., Nurul Fadila, S., Ananda, C., Alicia Farma. (2022). ‘Prosiding SEMNAS BIO 2021 Studi Literatur Mekanisme Perubahan Sel Normal Menuju Keganasan Sel Serta Peran Antioksidan Dalam Pencegahannya’, Prosiding Seminar Nasional Biologi , Vol1 No.2, pp. 1172–1181. Available at : https://semnas.biologi.fmipa.unp.ac.id/index.php/prosiding/article/view/296
Amtiria, H. R., Berawi, K. N. (2018). Peran Human Epidermal Growth Factor Receptor-2 pada Kanker Payudara, J Agromedicine Unila. Vol.5 No. 2. Available at : https://juke.kedokteran.unila.ac.id/index.php/agro/article/view/2127/pdf
Bello, M. (2021). Molecular recognition of tak-285 and lapatinib by inactive, active, and middle active-inactive HER2. Journal of Molecular Modeling, 27(4), 105. Available at: https://doi.org/10.1007/S00894-021-04720-5
Chakrabarty, A., Bhola, N. E., Sutton, C. R., Ghosh, R., Kuba, M. G., Dave, B., Chang, J. C., & Arteaga, C. L. (2013). Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Inhibitors. Cancer Research, 73(3), 1190–1200. https://doi.org/10.1158/0008-5472.CAN-12-2440
Chun, C.Y., Khor,S. X., Chia, A. Y., Tang, Y. (2023). In silico study of potential SARS-CoV-2 antagonist from Clitoria ternatea. Int J Health Sci. 17(3):3–10. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10155250/
Faure, C., Bouillie, R., Domingot, A., Segard, H., Taouji, S., Saidi, Y., Bernard, S, et al. (2021). ‘Allosteric inhibition of HER2 by moesin-mimicking compounds targets HER2-positive cancers and brain metastases’, Cancer Research, 81(21), pp. 5464–5476. Available at: https://doi.org/10.1158/0008-5472.CAN-21-0162.
Faure, C., Djerbi-Bouillié, R., Domingot, A., Bouzinba-Ségard, H., Taouji, S., Saidi, Y., Bernard, S., Carallis, F., Walther, R., Lenormand, J.-L., Chevet, É., & Bourdoulous, S. (2023). Data from Allosteric Inhibition of HER2 by Moesin-Mimicking Compounds Targets HER2-Positive Cancers and Brain Metastases. American Association for Cancer Research. Collection. Available at : https://doi.org/10.1158/0008-5472.c.6513291
Gaibar, M., Beltrán, L., Romero-Lorca, A., Fernández-Santander, A., & Novillo, A. (2020). Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer. Journal of Oncology, 6375956. Available at : https://doi.org/10.1155/2020/6375956
Hanahan, D., Weinberg, R.A. (2011). ‘Hallmarks of cancer: The next generation’, Cell, pp. 646–674. Available at: https://doi.org/10.1016/j.cell.2011.02.013.
Hudis, C.A. (2013). Trastuzumab-Mechanism of Action and Use in Clinical Practice. N Engl J Med 357(1):39-51. Available at: https://www.nejm.org/doi/abs/10.1056/NEJMra043186
Li, J., Wang, H., Li, J., Bao, J., Wu., C. (2016). Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer. Int. J. Mol. Sci, 17(7), 1055. Available at : https://doi.org/10.3390/ijms17071055
Lin, L., Gopal, S., Sharda, A., Passam, F., Bowley, S., Stopa, J., Xue, G, et al. (2015). ‘Quercetin-3-rutinoside Inhibits Protein Disulfide Isomerase by Binding to Its b′x Domain’, Journal of Biological Chemistry, 290(39), pp. 23543–23552. Available at: https://doi.org/10.1074/jbc.M115.666180.
Nakayama, A., Takagi, S., Yusa, T., Yaguchi, M., Hayashi, A., Tamura, T., Kawakita, Y., Ishikawa, T., Ohta, Y. (2013). ‘Antitumor Activity Of Tak-285, An Investigational,Non-Pgp Substrate Her2/Egfr Kinase Inhibitor, In Cultured Tumor Cells, Mouse And Rat Xenograft Tumors, And In An Her2-Positive Brain Metastasis Model’, Journal of Cancer, 4(7), pp. 557–565. Available at: https://doi.org/10.7150/jca.6689.
Naushafira, N. D., Hanuna., Dewi, M. K., Selius, W. V. N. (2022). ‘KAJIAN SISTEMATIK: AKTIVITAS KUERSETIN SEBAGAI INHIBITOR KANKER PAYUDARA SECARA IN VITRO Systematic Review: In Vitro Quercetin Activity as Breast Cancer Inhibitor’. Journal Of Research In Pharmacy Vol 2 Ed 3. Available at : https://doi.org/10.14710/genres.v2i2.15774
Risya, P., Putra, S., Prasetyo, A., Sinta, P., Wahyuni, E. (2022). ‘Potensi Kuersetin Terenkapsulasi PLGA Sebagai Terapi Dalam Penatalaksanaan Kanker Payudara’. Essence of Scientific Medical Journal, 20(1), pp. 35–42. Available at: https://ojs.unud.ac.id/index.php/essential/index.
Seo, H.S., Ku, J., Choi, H., Choi, Y., Woo, J., Kim, M., Kim, L., Na, C., Nur, H., Jang,B., Shin, Y., Ko, S. (2016). ‘Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in HER2-overexpressing BT-474 breast cancer cells’, Oncology Reports, 36(1), pp. 31–42. Available at: https://doi.org/10.3892/or.2016.4786.
Setiawan. H., Irawan. M. I. (2017). ‘Kajian Pendekatan Penempatan Ligan pada Protein Menggunakan Algoritma Genetika’, JURNAL SAINS DAN SENI ITS, 6, pp. 2337–3520. Available at : https://www.neliti.com/publications/485382/kajian-pendekatan-penempatan-ligan-pada-protein-menggunakan-algoritma-genetika
Soliman, A.M., Alqahtani, A.S. and Ghorab, M. (2019). ‘Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers’, Journal of Enzyme Inhibition and Medicinal Chemistry, 34(1), pp. 1030–1040. Available at: https://doi.org/10.1080/14756366.2019.1609469.
Son, S., Elkamhawy, A., Gul, A., Al-Karmalawy, A., Alnajjar, R., Abdeen, A., Ibrahim, S, et al. (2023). ‘Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines’, Journal of Enzyme Inhibition and Medicinal Chemistry, 38(1). Available at: https://doi.org/10.1080/14756366.2023.2202358.
Sung, H., Ferlay.J., Siegel. R., Laversanne. M., Soerjomataram. I., Jemal. A., Bray. F. (2021). ‘Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries’, CA: A Cancer Journal for Clinicians, 71(3), pp. 209–249. Available at: https://doi.org/10.3322/caac.21660.
Takagi, S., Banno, H., Hayashi, A., Tamura, T., Ishikawa, T., & Ohta, Y. (2014). HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285. Oncoscience 1(3), 196–204. Available at : https://doi.org/10.18632/ONCOSCIENCE.23
Verma, S., Goyal, S., Kumari, A., Kumari, A., Singh, A., Singh, A., Jamal, S., & Grover, A. (2018). Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants. PLOS ONE, 13(2). Available at : https://doi.org/10.1371/JOURNAL.PONE.0190942
Wang, G., Wang, Y., Yao, L., Gu, W., Zhao, S., Shen, Z., Lin, Z., Liu, W., Yan, T. (2022). ‘Pharmacological Activity of Quercetin: An Updated Review’, Evidence-based Complementary and Alternative Medicine. Hindawi Limited. Available at: https://doi.org/10.1155/2022/3997190.
Wang, Y., Xing, J., Xu, Y., Zhou, N., Peng, J., Xiong, Z., Liu, X., Luo, C., Chen, K., Zheng, M., Jiang, H. (2015). ‘In silico ADME/T modelling for rational drug design’, Quarterly Reviews of Biophysics. Cambridge University Press, pp. 488–515. Available at: https://doi.org/10.1017/S0033583515000190.
Zou, H., Luo, J., Guo, Y., Deng, L., Zeng, L., Pan, Y., & Li, P. (2024). Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer. Drug Resistance Updates, 73, 101051. Available at : https://doi.org/10.1016/j.drup.2024.101051
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Candra Rini Hasanah Putri
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The journal operates an Open Access policy under a Creative Commons Attribution-NonCommercial 4.0 International License. Author continues to retain the copyright if the article is published in this journal. The publisher will only need publishing rights. (CC-BY-NC 4.0)
